Anna’s biggest mistake was not reducing the trea
Post# of 36536
Generex needs to keep their focus simple. Look at $GSLI. We have without a doubt a better vaccine vs. GP2. They kept it focused- all messaging on data and CEO presentations. A clean spin out. National listing. Complete focus on what is wanted in biotech.
NGIO is the winning avenue. Vaccine development. Covid and get the AE37/ Keytruda of 20 patients going. No MSO or whatever until then. Focus laser point. Show success in true human studies. Raise the pps. All and only vaccine. No money in Arizona. Jmho. Be a holding company when you can afford it. And that’s after a spin out of NGIO. Just my opinion.